Press release
Anti-CD19 Antibody Pipeline 2026: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight
Anti-CD19 Antibody Pipeline
The report titled "Anti-CD19 Antibody Pipeline Insight, 2026" by DelveInsight provides a detailed overview of the current clinical landscape and future growth opportunities within the Anti-CD19 Antibody market.
The Anti-CD19 Antibody Pipeline report delivers a comprehensive clinical and commercial evaluation of candidates spanning preclinical stages to marketed therapies. It also includes detailed drug profiles covering mechanisms of action, clinical trial data, NDA approvals (where applicable), and development activities such as technology platforms, collaborations, mergers and acquisitions, funding, regulatory designations, and other key updates.
Request for free Anti-CD19 Antibody Pipeline sample report @ https://www.delveinsight.com/sample-request/anti-cd19-antibody-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Key Highlights from the Anti-CD19 Antibody Pipeline Report:
• Global pharmaceutical and biotech companies are actively progressing innovative Anti-CD19 Antibody therapies, achieving notable milestones in recent years.
• Companies engaged in this space include RemeGen, Caribou Biosciences, Precision Biosciences, TG Therapeutics, Xencor, Horizon Therapeutics, Morphosys, and several others advancing Anti-CD19-targeted treatments.
• Promising pipeline candidates across different clinical stages include RC58, CB-010, PBCAR19B, TG-1801, Obexelimab (XmAb5871), Inebilizumab, Tafasitamab, among others, which are anticipated to significantly influence the market landscape in the coming years.
• In December 2025, U.S. Food and Drug Administration approved a major label expansion for Amgen's autoimmune therapy Uplizna, enabling its use in adults with specific forms of generalized myasthenia gravis (gMG). This marked the therapy's second indication expansion in 2025, following earlier approval for IgG4-related disease in April. The approval applies to patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive, making Uplizna the first CD19-directed B-cell therapy authorized for this indication.
• In April 2025, Amgen's anti-CD19 antibody secured FDA approval for IgG4-related disease (IgG4-RD), becoming the first treatment indicated for this condition. Uplizna (inebilizumab-cdon) is approved for adult patients with IgG4-RD, a chronic immune-mediated inflammatory disorder that may lead to fibrosis and permanent organ damage. The regulatory decision was supported by findings from the Phase III MITIGATE trial, which enrolled 135 participants and demonstrated an 87% reduction in flare risk versus placebo during the 52-week controlled treatment period.
Anti-CD19 Antibody Overview
An anti-CD19 antibody is a monoclonal antibody designed to selectively bind to the CD19 protein expressed on B cells. CD19 plays a central role in B-cell activation, proliferation, and differentiation-key processes in immune responses, particularly antibody production.
Request a Free Sample PDF Report to Explore the Anti-CD19 Antibody Pipeline: https://www.delveinsight.com/report-store/anti-cd19-antibody-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Emerging Anti-CD19 Antibody Therapies in Clinical Development
• RC58 - RemeGen
• CB-010 - Caribou Biosciences
• PBCAR19B - Precision Biosciences
• TG-1801 - TG Therapeutics
• Obexelimab (XmAb5871) - Xencor
• Inebilizumab - Horizon Therapeutics
• Tafasitamab - Morphosys
Anti-CD19 Antibody Route of Administration (ROA)
The pipeline analysis categorizes therapies based on their routes of administration, including:
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
Anti-CD19 Antibody Molecule Classification
Pipeline products are further segmented by molecular type, such as:
• Oligonucleotides
• Peptides
• Small molecules
Anti-CD19 Antibody Pipeline Therapeutic Assessment Includes:
• Evaluation by Product Type
• Analysis by Development Stage and Product Type
• Assessment by Route of Administration
• Stage-wise ROA Segmentation
• Molecule Type Evaluation
• Stage-wise Molecule Classification
DelveInsight's report evaluates more than 12 products across various development stages, including:
• Late-stage candidates (Phase III)
• Mid-stage programs (Phase II)
• Early-stage therapies (Phase I)
• Preclinical and discovery-stage assets
• Discontinued or inactive programs
• Segmentation by route of administration
Download the Anti-CD19 Antibody Pipeline Report to Explore Emerging Therapies: https://www.delveinsight.com/sample-request/anti-cd19-antibody-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Leading Companies in the Anti-CD19 Antibody Therapeutics Space
Major players developing Anti-CD19-targeted therapies include:
• TG Therapeutics
• Merck KGaA
• Generium Pharmaceutical
• Sanofi
• Incyte Corporation
• Amgen
• Viela Bio
• And others
Anti-CD19 Antibody Pipeline Analysis
The report provides:
• Company-wise analysis of Anti-CD19 Antibody therapies under development.
• Segmentation of candidates into early, mid, and late clinical stages.
• Insights into active, dormant, and discontinued development programs.
• Classification by development stage, ROA, target receptor, monotherapy vs. combination therapy, mechanism of action, and molecular type.
• Detailed review of strategic collaborations (industry-industry and industry-academia), licensing agreements, and funding initiatives shaping the market's future.
The findings are compiled using proprietary databases, company and academic websites, clinical trial registries, conference proceedings, SEC filings, investor presentations, and official press releases, along with credible third-party industry sources.
Download a Sample PDF to Learn More About Anti-CD19 Antibody Drugs and Therapies: https://www.delveinsight.com/sample-request/anti-cd19-antibody-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Anti-CD19 Antibody Pipeline Market Drivers
• Increasing prevalence of B-cell malignancies
• Growing healthcare investments from public and private sectors
Anti-CD19 Antibody Pipeline Market Challenges
• Treatment-related adverse effects
• High therapy costs
• Additional clinical and regulatory complexities
Scope of the Anti-CD19 Antibody Pipeline Insight
• Geographical Coverage: Global
• Key Companies: RemeGen, Caribou Biosciences, Precision Biosciences, TG Therapeutics, Xencor, Horizon Therapeutics, Morphosys, and others
• Key Therapies: RC58, CB-010, PBCAR19B, TG-1801, Obexelimab (XmAb5871), Inebilizumab, Tafasitamab, and others
• Therapeutic Assessment: Marketed and emerging Anti-CD19 Antibody therapies
• Market Dynamics: Drivers and barriers influencing market expansion
Contact:
Ankit Nigam
anigam@delveinsight.com
+1 469 945 7679
Healthcare Consulting
https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a specialized business consulting and market research firm dedicated to the life sciences sector. The company assists pharmaceutical organizations with comprehensive, end-to-end strategic solutions designed to enhance performance and drive sustainable growth. Its healthcare consulting services enable data-driven market analysis, strategic planning, and practical solutions to address evolving industry challenges.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Anti-CD19 Antibody Pipeline 2026: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight here
News-ID: 4405016 • Views: …
More Releases from DelveInsight Business Research
Erectile Dysfunction Market Growth Outlook 2034: Epidemiology, Pipeline Therapie …
DelveInsight's "Erectile Dysfunction Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Erectile Dysfunction, historical and forecasted epidemiology as well as the Erectile Dysfunction market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Erectile Dysfunction market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Erectile Dysfunction Market Forecast
https://www.delveinsight.com/sample-request/erectile-dysfunction-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav
Some of the…
Degenerative Disc Disease Pipeline 2026: FDA Approvals and Clinical Trials Lands …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Degenerative Disc Disease pipeline constitutes 15+ key companies continuously working towards developing 15+ Degenerative Disc Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Degenerative Disc Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase.…
Charcot Marie Tooth Disease Pipeline 2026: Therapies, MOA Insights, and Key Clin …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Charcot Marie Tooth Disease pipeline constitutes 13+ key companies continuously working towards developing 15+ Charcot Marie Tooth Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Charcot Marie Tooth Disease Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across…
Stargardt Disease Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and Clinical Tria …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Stargardt Disease pipeline constitutes 20+ key companies continuously working towards developing 20+ Stargardt Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Stargardt Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also…
More Releases for CD19
CD19 CAR-T Therapy Achieves Triple Remission in Refractory Autoimmune Diseases
Doctors often reach a stalemate when they manage B cell-driven autoimmune diseases (AIDs). Standard therapies like steroids and rituximab frequently fail to provide durable relief for these patients. These traditional treatments result in incomplete responses. Because they do not achieve a total reset of the immune system, the patient eventually relapses. However, recent progress in cellular engineering has introduced CD19 CAR-T cell therapy. This is a potent intervention for refractory…
CD19 Therapeutics Market Key Players, Therapeutic Approaches, and Market Dynamic …
The CD19 Therapeutics Market focuses on treatments targeting CD19, a surface protein expressed predominantly on B cells, making it a highly effective and validated therapeutic target for various B-cell malignancies, including acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), and certain autoimmune disorders. CD19-directed therapies have transformed hematologic cancer care due to their exceptional response rates-especially in relapsed or refractory patient populations.
Market…
CD19 Therapeutics Market to Reach USD 21.4 Billion by 2034, Growing at 12.0% CAG …
Introduction
The global healthcare landscape is undergoing a revolutionary transformation with the growing adoption of immuno-oncology and targeted biologics, particularly therapies directed against the CD19 antigen. CD19, a cell surface protein expressed in B-lineage cells, has become one of the most promising therapeutic targets for the treatment of B-cell malignancies, including leukemia, lymphoma, and autoimmune diseases. As precision medicine advances, CD19-directed therapies-encompassing monoclonal antibodies, bispecific antibodies, and cell-based treatments-are redefining cancer…
Cd19 Antibody Market Forecast Regions, Product Innovations, and Growth Till 2032
The latest WGR report, "Cd19 Antibody Market Report 2024: Market Size, Trends, and Global Forecast 2024-2032," provides an in-depth analysis of market dynamics, investment opportunities, and the competitive landscape. According to WGR's analysis, by the end of 2032, the Cd19 Antibody market is expected to reach a valuation of USD 4 billion. Additionally, the report forecasts that the market will expand at a CAGR of 9.03% from 2024 to 2032.
The…
Global CD19 Antibody Market and Clinical Pipeline Outlook 2028
Global CD19 Antibody Market and Clinical Pipeline Outlook 2028 Report Highlights:
* Global CD19 Antibody Market Opportunity: > USD 10 Billion By 2028
* Commercially Approved CD 19 Antibodies: 10 Antibodies
* Annual, Quarterly and Regional Sales Insight On Approved CD19 Antibodies
* Dosage and Price Insight On Approved CD19 Antibodies
* Comprehensive Insights On CD19 Antibodies In Clinical Trials: > 190 Antibodies
* Global CD19 Antibodies Clinical Trials By Company, Indication and Phase
* Competitive Landscape:…
Anti-CD19 Market Projected to Show Strong Growth | Bellicum Phamaceuticals, Morp …
Advance Market Analytics published a new research publication on "Anti-CD19 Market Insights, to 2028" with 232 pages and enriched with self-explained Tables and charts in presentable format. In the Study you will find new evolving Trends, Drivers, Restraints, Opportunities generated by targeting market associated stakeholders. The growth of the Anti-CD19 market was mainly driven by the increasing R&D spending across the world. Some of the key players profiled in the…
